SEOUL, South Korea, Jan. 24 /PRNewswire/ -- As the 1st leading company, Dong-A Pharmaceutical Co., Ltd. (Representative Mr. Won-Bae Kim) announced that Dong-A Pharmaceutical has been granted a COS(Certificate of Suitability of Monographs of the European Pharmacopoeia) for Epirubicin Hydrochloride, which is an active anticancer ingredient approved by the European directorate for the Quality of Medicines (EDQM).
The action mechanism helps Epirubicin HCL bind to DNA to inhibit the nucleic acid synthesis.
As the second generation anticancer ingredient which improved the side effects of the first generation anticancer ingredient, Doxorubicin, it is broadly used to treat some kinds of breast, stomach and lung cancers.
Also, COS(Certification of Suitability of Monographs of the European Pharmacopoeia) is a certificate that certifies the compliance of a material with the requirements laid down in the relevant monograph of the European Pharmacopoeia.
Dong-A Pharmaceutical Co., Ltd. expects that it is planning to enter into the European market with this COS of Epirubicin HCL and also its total sale will be more than 30 million dollars in global markets such as Latin America, India, and Australia.
Contact : Seong-Yeol Lee Assistant Manager ETC Export Dept. International Business Div. Phone : +82 2 920 8368 HP : +82 19 493 5711 Fax : +82 2 924 2662 e-Mail : esy@donga.co.kr Internet: www.donga.co.kr
Dong-A Pharmaceutical Co., Ltd.
CONTACT: Seong-Yeol Lee, Assistant Manager, ETC Export Dept.,International Business Div., Phone - +82-2-920-8368, HP - +82-19-493-5711,Fax - +82-2-924-2662, esy@donga.co.kr
Web site: http://www.donga.co.kr/
